Microsatellites in the Estrogen Receptor (ESR1, ESR2) and Androgen Receptor (AR) Genes and Breast Cancer Risk in African American and Nigerian Women

Yonglan Zheng¹, Dezheng Huo², Jing Zhang¹, Toshio F. Yoshimatsu¹, Qun Niu¹, Olufunmilayo I. Olopade¹*

1 Center for Clinical Cancer Genetics and Global Health, Department of Medicine, The University of Chicago, Chicago, Illinois, United States of America, 2 Department of Health Studies, The University of Chicago, Chicago, Illinois, United States of America

Abstract
Genetic variants in hormone receptor genes may be crucial predisposing factors for breast cancer, and microsatellites in the estrogen receptor (ESR1, ESR2) and androgen receptor (AR) genes have been suggested to play a role. We studied 258 African-American (AA) women with breast cancer and 259 hospital-based controls, as well as 349 Nigerian (NG) female breast cancer patients and 296 community controls. Three microsatellites, ESR1_TA, ESR2_CA and AR_CAG, in the ESR1, ESR2 and AR genes, respectively, were genotyped. Their repeat lengths were then analyzed as continuous and dichotomous variables. Analyses of continuous variables showed no association with breast cancer risk in either AA or NG at ESR1_TA; AA cases had shorter repeats in the long allele of ESR2_CA than AA controls (Mann-Whitney P = 0.036; logistic regression P = 0.04, OR = 0.91, 95% CI 0.83–1.00), whereas NG patients had longer repeats in the short allele than NG controls (Mann-Whitney P = 0.0018; logistic regression P = 0.04, OR = 1.06, 95% CI 1.00–1.11), and AA cases carried longer repeats in the short allele of AR_CAG than AA controls (Mann-Whitney P = 0.036; logistic regression P = 0.03, OR = 1.08, 95% CI 1.01–1.15). When allele sizes were categorized as dichotomous variables, we discovered that women with two long alleles of ESR2_CA had increased risk of breast cancer (OR = 1.38, 95% CI 1.10–1.74; P = 0.006). This is the first study to investigate these three microsatellites in hormonal receptor genes in relation to breast cancer risk in an indigenous African population. After adjusting for multiple-testing, our findings suggest that ESR2_CA is associated with breast cancer risk in Nigerian women, whereas ESR1_TA and AR_CAG seem to have no association with the disease among African American or Nigerian women.

Introduction
Breast cancer is a major global problem, as it is one of the most commonly diagnosed cancers among women. In the United States, breast cancer is the first leading and the second fatal cancer among female cancer patients [1], while in western Africa, breast cancer has the second highest incidence and death rates [2]. Given the complex and comprehensive nature of breast cancer, it is reasonable to hypothesize that a joint effect of genetic factors as well as endogenous and exogenous hormonal and other environmental factors could contribute to an increased risk for breast cancer development.

Attention has long been paid to hormonal influences in breast cancer pathogenesis. Substantial evidence from both epidemiologic and experimental studies demonstrates a crucial role of hormones in the etiology of breast cancer. The indirect epidemiologic support has come from the link between established reproductive breast cancer risk factors, such as early age at menarche and late age at menopause, and the exposures to estrogens and progesterone [3]. Consistent observations of higher levels of circulating estrogens and androgens in postmenopausal breast cancer women compared with controls provide the direct epidemiological evidence of hormones and breast cancer risk, whereas the link between sex steroids and premenopausal breast cancer risk still remains unclear [4]. Laboratory studies have shown that estrogens contribute to breast carcinogenesis via estrogen receptor (ER)-mediated cell proliferation, genotoxic effects of the metabolites, or the induction of aneuploidy [5]. Androgens have been suggested to influence breast cancer risk, either by directly binding to androgen receptors and either increasing or decreasing breast cell growth and proliferation, or by binding indirectly, through their conversion to estradiol or competitive binding to ER-α [6].

Microsatellites/short tandem repeats (STRs) are informative genetic markers in the human genome and they could have biological functions according to their locations, such as affecting protein coding (in coding regions), or regulating gene expression (in regulatory regions) [7]. Microsatellites in the estrogen receptor (ESR1, ESR2) and androgen receptor (AR) genes have been hypothesized to be predisposing factors for breast cancer but the mechanisms are unknown. A dinucleotide TA repeat polymorphism
(ESR1_TA) is located in the promoter region of ESR1 isoforms 1 and 2, as well as intron 1 and intron 2 of ESR1 isoforms 3 and 4, respectively (6q23.1), while a polymorphic dinucleotide CA tandem repeat (ESR2_CA) is located in intron 5 of ESR2 (1q23.2). To date, the functional property of these two microsatellites remains unknown, although gene expression could be modulated by such repeat nucleotide sequences [7]. AR (Xq12) is a ligand-dependent transcription factor, and its first exon contains a trimucleotide CAG repeat (AR_CAG) which has been of active interest, compared to ESR1_TA and ESR2_CA. AR_CAG encodes a polyglutamine (PolyGln) tract in the N-terminal transactivation domain of the AR protein, and it has been elucidated that PolyGln length inversely correlates with AR transcriptional competence [8]. Over the last decade, intensive association studies have been conducted to test the relationship between these three microsatellites and breast cancer risk in men and women, predominantly focusing on AR_CAG (Table 1). However, the results are controversial due to different study designs and different races/ethnicities of the study subjects, as a population-specific manner could exist. In addition, most of the previous study populations were Caucasians, some were Asians, and only one study population was African American (Table 1).

In the present study, we aimed to investigate whether ESR1_TA, ESR2_CA, and AR_CAG could be breast cancer susceptibility markers in African American (AA) and Nigerian (NG) women. We used a case-control study design with 250 AA cases and 259 AA controls, together with 349 NG cases and 296 NG controls.

Materials and Methods

Ethics Statement

Informed consent was written and obtained from all participants. This study was approved by the Institutional Review Boards of the University of Chicago and the University of Ibadan.

Study Populations

The Chicago Cancer Prone Study (CCPS): CCPS is an ongoing hospital-based case-control study aimed at understanding the genetic basis of young-onset breast cancer. Histologically confirmed breast cancer patients were recruited through the Cancer Risk Clinic at the University of Chicago. Cancer-free healthy controls were gender- and age-matched with cases and enrolled from individuals who visited the same hospital (Translational Research Initiative in the Department of Medicine, TRIDOM). Included in this study were 258 AA cases (age of onset = 44.1±10.0 years [mean ± SD]) and 259 AA controls (age = 46.8±10.9 years).

The Nigerian Breast Cancer Study (NBCS): NBCS is an ongoing case-control study of breast cancer in Ibadan, Nigeria initiated in 1998. Breast cancer patients were recruited at the University College Hospital, Ibadan. Cancer-free healthy controls were randomly collected from a community adjoining the hospital, gender- and age-matched to the cases in the present study. The majority of the study subjects are Yoruban from Ibadan. NBCS contributed 349 NG cases (age of onset = 47.5±11.7 years) and 296 NG controls (age = 41.5±14.1 years) to this study.

Unfortunately, estrogen receptor (ER) status was available for only a small subset of the breast cancer cases: 88 AA ER+ cases, 86 AA ER- cases, 23 NG ER+ cases, and 48 NG ER- cases (Table S1 and Table S2).

Sample Quality Control

Genomic DNA was extracted from whole blood and evaluated for integrity by electrophoresis on agarose gel. Double-strand DNA was quantitated using Quant-iT™ PicoGreen dsDNA kit (Invitrogen, CA, USA) and then quantified on Infinite® 200 PRO NanoQuant (Tecan, Manfredorf, Switzerland), according to the manufacturer’s instructions. To examine the potential sample contamination and gender discrepancy, samples were amplified by polymerase chain reaction (PCR) using AmpFSTR® Identifiler® PCR Amplification kit (Applied Biosystems, CA, USA) and the PCR products were analyzed on Applied Biosystems 3130 DNA Analyzer (Applied Biosystems, CA, USA). DNA fragment data were collected and then individually checked using GeneMapper® software (Applied Biosystems, CA, USA), according to the manufacturer’s protocol.

Determination of Microsatellite Allele Sizes

Primers were designed to amplify the fragments encompassing microsatellites ESR1_TA, ESR2_CA and AR_CAG present in ESR1, ESR2 and AR, respectively: ESR1_TA_F: 5'-6FAM-AGAGGCGATGATACCTCACC-3', ESR1_TA_R: 5'-GTT-CACCTGCGGTAGGATAT-3' [amplicons: chr:152127623–152127811, GRCh37/hg19]; ESR2_CA_F: 5'-HEX-AACAAATGTTGAATGAGTTGCC-3', ESR2_CA_R: 5'-GGTTAAGCATGGTCTGTACC-3' [amplicons: chr:64720235–64720395, GRCh37/hg19]; AR_CAG_F: 5'-HEX-TCCGAAATCTGTCCTACGAGCGTG-3', AR_CAG_R: 5'-GCTGTGAAAGTGGTGTCACAGAACATCAT-3' [amplicons: chrX:66750506–66753343, GRCh37/hg19]. PCR was performed using PCRx Enhancer System (Invitrogen, CA, USA) with conditions as follows: initial denaturation at 95°C for 5 min, followed by 35 amplification cycles at 95°C for 30 sec, annealing at 55°C for 50 sec and 72°C for 50 sec, followed by a final extension step at 72°C for 10 min. Fluorescently labeled fragments generated by PCR were run on Applied Biosystems 3130 DNA Analyzer and the repeat lengths were subsequently checked and assigned in GeneMapper® software. Genotypes were determined by two independent investigators who were blinded to subject disease status and all clinical information. Multiple homozygous subjects for each individual microsatellite were randomly chosen from the same studied populations and sequenced. Repeat lengths read by sequencing were successfully assigned to corresponding peak positions determined by fluorescence-based genotyping. Ninety-six samples were randomly selected and repeated to test the assay reproducibility.

Post-genotyping Quality Measurements

Tests of conformance to Hardy-Weinberg genotypic expectations were carried out with Genepop v.4.1 [available at http://genepop.curtin.edu.au/]. In addition, we checked the microsatellite data by Micro-Checker v2.2.3, which was designed to identify genotyping errors due to an excess of homozygotes caused by non-amplified alleles (null alleles), stutter peaks, or short allele dominance (large allele dropout) [available at http://www.microchecker.hull.ac.uk/]. Genotypes that did not deviate from Hardy-Weinberg Equilibrium (HWE) were eligible for statistical association analyses.

Statistical Analysis

The repeat lengths for ESR1_TA, ESR2_CA and AR_CAG were classified as continuous and categorical variables, separately. For the continuous variable analysis, two alleles of a single microsatellite carried by each woman were assigned as the short...
Table 1. Summary of the literature about ESR1_TA, ESR2_CA, and AR_CAG microsatellites and breast cancer risk.

| Author, year | Study type | Major population | Affected/Unaffected | Sample notes | DNA | Major dichotomous repeat cutoff | Main findings |
|--------------|------------|------------------|--------------------|--------------|-----|-------------------------------|--------------|
| Wedren, 2004 | Case-control | Swedish | 1514/1514 | Female, postmenopausal | Somatic, germline | 14 | Deviance from HWE |
| Iobagiu, 2006 | Case-control | French | 139/145 | Female | Germline | 19 | No association |
| Anghel, 2006 | Case-control | Romanian | 153/318 | Female | Somatic, germline | 16, 23, 38 (sum) | Shorter repeats higher risk |
| Tsezou, 2008 | Case-control | Greek | 79/155 | Female | Germline | 15 | No association |
| Forst, 2003 | Case-control | Finnish | 219/248 | Female cases and male controls | Germline | NA | No association |
| Iobagiu, 2006 | Case-control | French | 139/145 | Female | Germline | 22 | No association |
| Anghel, 2006 | Case-control | Romanian | 153/318 | Female | Somatic, germline | 22, 23, 45 (sum) | Shorter repeats higher risk |
| Tsezou, 2008 | Case-control | Greek | 79/155 | Female | Germline | 20 | Longer repeats less risk |
| Rebbec, 1999 | Case-control | American | 165/139 | Female, BRCA1 mutation carriers | Germline | 28 | Longer repeats higher risk and earlier diagnosis |
| Spurdle, 1999 | Case-control | Australian | 368/284 | Female, <40 years | Germline | 22 | No association overall, or stratified by family history, ER and PR status |
| Dunning, 1999 | Case-control | British | 508/426 | Female | Germline | 21, 28 | No association |
| Young, 2000 | Case-control | Scotch | 59/79 | Male | Somatic, germline | NA | No association |
| Given, 2000 | Case only | Irish | 178/- | Female, ≤65 years | Germline | 28 | No association |
| Yu, 2000 | Case only | Italian | 133/- | Female | Somatic | 21, 44 (sum) | Longer repeats associated with lower grade of tumors, fewer lymph node metastases and longer survival |
| Menin, 2001 | Case only | Italian | 101+50/- | Some BRCA1/2 mutation carriers, 50 ovarian cancers | Germline | 19, 23 | No association |
| Kadouri, 2001 | Case-control | Ashkenazi Jewish | 152+166/36+152 | Female, 188 BRCA1/2 mutation carriers including ovarian cancers | Germline | 28 | No association |
| Giguère, 2001 | Case-control | French-Canadian | 255/461 | Female | Germline | 20, 39 (sum) | Shorter repeats less risk, association stronger in postmenopausal women |
| Elhaji, 2001 | Case-control | Canadian | 114/248 | Female, >40 years | Somatic, germline | 26 | Longer repeats higher risk in well and moderately differential tumors |
| Kristiansen, 2002 | Case-control | Norwegian | 216/575 | Female, heterozygous cases for the CAG repeat | Germline | 30 | No association |
| Haiman, 2002 | Case-control | European-American | 727/969 | Female, predominantly postmenopausal | Germline | 22 | No association overall, longer repeats associated with family history |
| Dagan, 2002 | Case-control | Israeli Jewish | 108+41/78 | Female, BRCA1/2 mutation carriers, 41 ovarian cancers | Germline | 18, 19 | Shorter repeats earlier onset |
| Author, year    | Study type     | Major population        | Affected/Unaffected | Sample notes                                                                 | DNA              | Major dichotomous repeat cutoff | Main findings                                                                                   |
|----------------|----------------|-------------------------|---------------------|-----------------------------------------------------------------------------|------------------|--------------------------------|--------------------------------------------------------------------------------|
| Suter, 2003 [41] | Case-control   | European-American       | 524/461             | Female, <45 years                                                          | Gemline          | 22, 43 (sum)                   | Longer repeats higher risk, homozygous of CAG short allele associated with ever use of oral contraceptives |
| Syrjakoski, 2003 [42] | Case only     | Finnish                 | 32/2                | Male                                                                        | Gemline          | NA                             | No association                                                               |
| Liede, 2003 [43] | Case-control   | Filipino                | 299/229             | Female                                                                      | Gemline          | 25                             | Longer repeats higher risk                                                  |
| MacLean, 2004 [44] | Case only     | Australian              | 41/2               | Male                                                                        | Somatic          | 24                             | Longer repeats are more frequent in patients with grade I and II tumors, but not associated with age at diagnosis |
| Spurdle, 2004 [45] | Case-control   | Australian & British    | 331+32/241          | Female, BRCA1/2 mutation carriers, 32 ovarian caners                      | Gemline          | 28, 29                         | No association                                                               |
| Wang, 2005 [9] | Case-control   | African-American        | 239/                | Female                                                                      | Gemline          | 22                             | No association overall, longer repeats associated with family history          |
| Iobagiu, 2006 [15] | Case-control   | French                  | 249139/145          | Female                                                                      | Gemline          | 15                             | Shorter repeats higher risk                                                  |
| Anghel, 2006 [24] | Case-control   | Romanian                | 153/318             | Female                                                                      | Somatic, germline | 13, 16, 28 (sum) | Longer repeats higher risk                                                  |
| Cox, 2006 [27] | Case-control   | European-American & European | 95+376+669/540+674 | Female                                                                        | Gemline          | 22, 23, 25, 27                | No association                                                               |
| Slattery, 2007 [46] | Case-control   | European-American & Hispanic-American | 1,169+576/1,330+725 | Female                                                                      | Gemline          | 22                             | No association                                                               |
| González, 2007 [47] | Case-control   | Spanish                 | 257/393             | Female                                                                      | Gemline          | 22                             | Longer repeats higher risk                                                   |
| Wedrén, 2007 [48] | Case-control   | Swedish                 | 1,542/1,511         | Female, postmenopausal                                                     | Somatic, germline | 22, 20                         | No association overall                                                       |
| Tsezou, 2008 [16] | Case-control   | Greek                   | 79/155              | Female                                                                      | Gemline          | 22                             | Longer repeats less risk                                                      |
| Wu, 2008 [49] | Case-control   | Taiwanese               | 88/334              | Female                                                                      | Gemline          | 22                             | Longer repeats associated with short duration of early estrogen exposure      |
| Abbas, 2010 [50] | Case-control   | Germany                 | 3,149/5,489         | Female                                                                      | Gemline          | 22                             | Shorter repeats associated with combined estrogen-progestagen therapy        |
| Chintamani, 2010 [51] | Case-control   | Indian                  | 70/80               | Female                                                                      | Gemline          | NA                             | No association                                                               |
| Sakoda, 2010 [52] | Case-control   | Chinese                 | 614+467/879         | Female, 467 subjects with fibrocystic conditions                          | Gemline          | 22–24                          | Longer repeats associated with an increased risk of fibrocystic breast conditions |
| Hietala, 2010 [53] | htSNP/diplotype | Swedish                 | 56/269              | Female, 56 BRCA1/2 mutation carriers and 269 young healthy subjects from breast cancer high-risk families | Gemline          | 22                             | Neither individual htSNPs nor other diplotype were significantly associated with androgen levels and did not tag for AR microsatellites |
| Rajender, 2010 [54] | Case-control   | Indian                  | 747/661             | Female                                                                      | Gemline          | NA                             | No association overall, no significant difference between pre- and post-menopausal cases |
| Mehdipour, 2010 [55] | Case-control   | Iranian                 | 500/432             | Female                                                                      | Gemline          | 22                             | Longer repeats higher risk                                                   |
| Gilbert, 2011 [56,57] | Case-control   | Egyptian                | 44/43               | Male                                                                        | Somatic, germline | 14, 22                         | No association                                                               |

doi:10.1371/journal.pone.0040494.t001
allele (S) and the long allele (L), according to the smaller and larger allele sizes determined, respectively. For homozygotes, two alleles are identical in peak positions; they were assigned as one S and one L, and later included in both the short and long allele analyses. For each microsatellite, the repeat lengths (mean ± standard deviation [SD]) were calculated under three categories: S, L, and the average of them. Wilcoxon rank-sum (Mann-Whitney) test was applied to compare the distributions of the repeat lengths, between case and control groups of AA and NG. Van Elteren’s test which is a stratified version of Wilcoxon rank-sum test was used to compare the repeat length in the pooled AA and NG sample set. Odds ratios (ORs) were also calculated by logistic regression analysis controlling for ascertainment, and with 95% confidence interval (CI) for three microsatellites, in AA, NG, and AA + NG. In addition, in order to avoid too-strong assumptions allele sizes were classified into dichotomous groups. Given that there is no a priori cut-off point applicable to distinguish satisfactorily the short and long alleles for ESR1_TA, ESR2_CA or AR_CAG, the mean repeat lengths of these three microsatellites in control groups were chosen as cut-off points, respectively. The cut-off limits were 18 (S: < 18, L: ≥ 18) for ESR1_TA, 23 (S: < 23, L: ≥ 23) for ESR2_CA, and 20 (S: < 20, L: ≥ 20) for AR_CAG (see Results and Table 2). The comparisons of genotype distributions between case and control groups were then performed in unconditional logistic regression models for AA and NG separately and as pooled samples, based on the categorical variables corresponding to the three microsatellites. Further, a cut-off point of 22 for AR_CAG was also chosen in an attempt to allow direct comparison of our results to the data previously reported in the literature. Moreover, since Wang and colleagues have conducted the association test between AR_CAG and breast cancer risk in AA using a dichotomized cut-off point of 22 [9], we also compared our data to theirs to see whether the findings were consistent in the same ethnic population. Moreover, we conducted a similar analysis for the ER status of breast cancer cases. Given the limited sample size, we combined AA and NG for both continuous and categorical variable analyses stratified by ER status (Table S1 and Table S2). The statistical analysis was conducted using Stata 11.1 software (StataCorp, TX, USA) and SAS 9.2 package (SAS Institute, NC, USA). All statistical tests were two-sided. Given three tested loci and two populations, the number of multiple-testing was 6. Thus, the significant threshold was set as 0.05/6 = 0.0083.

Results

Genotyping Quality

No samples were detected to have contamination or gender issues, no discrepancy of allele calling was found between two investigators, and genotypes of 96 repeated samples were 100% consistent with previous determinations. Genotyping call rates were 99.8%, 100%, and 100% for ESR1_TA, ESR2_CA, and AR_CAG, respectively, in AA; genotyping call rates were 99.5%, 100%, and 99.8% for ESR1_TA, ESR2_CA, and AR_CAG, respectively, in NG. Calculations from Genepop and Microchecker showed that genotypes for all three microsatellites were in HWE and no potential genotyping errors were detected.

Distribution of ESR1_TA Alleles in Cases and Controls

The repeat length of ESR1_TA ranged from 9 to 26 (S: 9–24; L: 9–26) in AA cases and 9 to 26 (S: 9–24; L: 13–26) in AA controls, whereas the range was 9 to 27 (S: 9–23; L: 13–27) in NG cases and 9 to 25 (S: 9–23; L: 13–25) in NG controls. The repeat lengths (mean ± SD) of ESR1_TA were 17.31 ± 2.86 and 17.36 ± 2.78 in AA cases and controls, respectively; repeat lengths

| Microsatellite | Allele | AA Case | NG Case | AA Control | NG Control | AA + NG | Mann-Whitney p² | OR (95% CI) | Allele |
|---------------|--------|---------|---------|------------|------------|---------|----------------|-------------|--------|
| ESR1_TA       | S      | 19.32±0.03 | 15.01±0.77 | 14.78±2.66 | 14.78±2.66 | 15.01±0.77 | 0.01±0.01 | 0.18 | 0.18 |
| ESR1_TA       | L      | 19.31±0.26 | 17.98±2.78 | 17.13±2.53 | 17.13±2.53 | 17.98±2.78 | 0.01±0.01 | 0.22 | 0.22 |
| ESR2_CA       | S      | 21.36±2.02 | 21.26±3.01 | 21.29±2.03 | 21.29±2.03 | 21.29±2.03 | 0.01±0.01 | 0.37 | 0.37 |
| ESR2_CA       | L      | 21.36±2.02 | 21.52±2.05 | 21.52±2.05 | 21.52±2.05 | 21.52±2.05 | 0.01±0.01 | 0.35 | 0.35 |
| AR_CAG        | S      | 18.35±2.98 | 22.23±3.98 | 22.23±3.98 | 22.23±3.98 | 22.23±3.98 | 0.01±0.01 | 0.19 | 0.19 |
| AR_CAG        | L      | 18.35±2.98 | 22.23±3.98 | 22.23±3.98 | 22.23±3.98 | 22.23±3.98 | 0.01±0.01 | 0.17 | 0.17 |

Table 2. Continuous variable analysis of ESR1_TA, ESR2_CA, and AR_CAG alleles and breast cancer risk in African American and Nigerian women.
were $17.18 \pm 2.76$ and $17.13 \pm 2.53$ in NG cases and controls, respectively (Table 2, Figure 1).

No significant difference in the distribution of ESR1_TA repeat length was observed between cases and controls in AA or NG, when the continuous variable analysis was performed classifying allele sizes to S, L, and Ave. (Table 2). We also dichotomized the repeat length based on the cut-off point of 22, which was the mean of repeat length in AA and NG controls. There was no significant association in the ESR1_TA genotype distribution in either AA or NG. Instead, we found a $P$ value of 0.039 in logistic regression in the pooled sample set of AA + NG, but it did not retain significance after correction for multiple-testing (Table 3).

Distribution of ESR2_CA Alleles in Cases and Controls

The repeat length of ESR2_CA ranged from 9 to 31 [S: 9–26; L: 18–31; average [Ave.] 22.61 ± 1.74] in AA cases and 9 to 34 [S:

---

**Figure 1. Allele distributions of ESR1_TA, ESR2_CA, and AR_CAG in AA and NG.** (A) ESR1_TA allele distribution in AA. (B) ESR1_TA allele distribution in NG. (C) ESR2_CA allele distribution in AA. (D) ESR2_CA allele distribution in NG. (E) AR_CAG allele distribution in AA. (F) AR_CAG allele distribution in NG.

doi:10.1371/journal.pone.0040494.g001
Table 3. Categorical variable analysis of ESR1_TA, ESR2_CA, and AR_CAG alleles and breast cancer risk in African American and Nigerian women.

| Microsatellite | Dichotomous cut-off | Genotype | Logistic regression | Logistic regression | Logistic regression |
|---------------|---------------------|----------|---------------------|---------------------|---------------------|
|               |                     |          |                     |                     |                     |
|               |                     |            | Case, n (%) | Control, n (%) | OR (95% CI) | Case, n (%) | Control, n (%) | OR (95% CI) | Case, n (%) | Control, n (%) | OR (95% CI) |
| ESR1_TA       | < 18 vs. ≥18        | SS        | 90 (35.0) | 84 (32.4) | 1.0 (ref.) | 123 (35.2) | 88 (30.0) | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) |
|               |                     | SL        | 115 (44.8) | 138 (53.3) | 0.78 (0.53–1.15) | 173 (49.6) | 164 (56.0) | 0.75 (0.53–1.07) | 0.77 (0.59–0.99) | 0.77 (0.59–0.99) | 0.77 (0.59–0.99) |
|               |                     | LL        | 52 (20.2) | 37 (14.3) | 1.31 (0.78–2.20) | 53 (15.2) | 41 (14.0) | 0.92 (0.57–1.51) | 1.09 (0.77–1.56) | 1.09 (0.77–1.56) | 1.09 (0.77–1.56) |
|               |                     | Total     | 257       | 259       | 0.089        | 349       | 293       | 0.26        | 0.039       | 0.039       | 0.039       |
|               |                     | LL vs. SS + SL | 1.52 (0.96–2.42) | 0.075 | 1.10 (0.71–1.71) | 0.67 | 1.29 (0.93–1.77) | 0.12 |
|               |                     | SL + LL vs. SS | 0.89 (0.62–1.28) | 0.53 | 0.79 (0.57–1.10) | 0.16 | 0.83 (0.65–1.07) | 0.15 |
| ESR2_CA       | < 23 vs. ≥23        | SS        | 26 (10.1) | 22 (8.5) | 1.0 (ref.) | 29 (8.3) | 28 (9.5) | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) |
|               |                     | SL        | 111 (43.0) | 113 (43.6) | 0.83 (0.44–1.55) | 125 (35.8) | 148 (50.0) | 0.82 (0.46–1.44) | 0.82 (0.46–1.44) | 0.82 (0.46–1.44) | 0.82 (0.46–1.44) |
|               |                     | LL        | 121 (46.9) | 124 (47.9) | 0.83 (0.44–1.54) | 195 (55.9) | 120 (40.5) | 1.57 (0.89–2.77) | 1.17 (0.77–1.78) | 1.17 (0.77–1.78) | 1.17 (0.77–1.78) |
|               |                     | Total     | 258       | 259       | 0.82        | 349       | 296       | 0.0004      | 0.016       | 0.016       | 0.016       |
|               |                     | LL vs. SS + SL | 0.96 (0.68–1.36) | 0.82 | 1.66 (1.36–2.54) | <0.001 | 1.38 (1.10–1.74) | 0.006 |
|               |                     | SL + LL vs. SS | 0.83 (0.46–1.50) | 0.54 | 1.15 (0.67–1.99) | 0.61 | 0.99 (0.66–1.48) | 0.97 |
| AR_CAG        | < 20 vs. ≥20        | SS        | 66 (25.0) | 61 (23.6) | 1.0 (ref.) | 101 (29.0) | 87 (29.5) | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) |
|               |                     | SL        | 125 (48.4) | 138 (53.3) | 0.84 (0.55–1.28) | 180 (51.7) | 154 (52.2) | 1.01 (0.70–1.44) | 0.93 (0.71–1.22) | 0.93 (0.71–1.22) | 0.93 (0.71–1.22) |
|               |                     | LL        | 67 (26.0) | 60 (23.2) | 1.03 (0.63–1.69) | 67 (19.3) | 54 (18.3) | 1.07 (0.68–1.69) | 1.06 (0.76–1.48) | 1.06 (0.76–1.48) | 1.06 (0.76–1.48) |
|               |                     | Total     | 258       | 259       | 0.54        | 348       | 295       | 0.95        | 0.67        | 0.67        | 0.67        |
|               |                     | LL vs. SS + SL | 1.16 (0.78–1.74) | 0.46 | 1.06 (0.72–1.58) | 0.76 | 1.11 (0.84–1.48) | 0.46 |
|               |                     | SL + LL vs. SS | 0.90 (0.60–1.34) | 0.59 | 1.02 (0.73–1.44) | 0.90 | 0.97 (0.75–1.25) | 0.90 |
| AR_CAG        | < 22 vs. ≥22        | SS        | 124 (48.1) | 127 (49.0) | 1.0 (ref.) | 192 (55.2) | 155 (52.5) | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) | 1.0 (ref.) |
|               |                     | SL        | 102 (39.5) | 110 (42.5) | 0.95 (0.66–1.37) | 130 (37.4) | 122 (41.4) | 0.86 (0.62–1.19) | 0.90 (0.70–1.15) | 0.90 (0.70–1.15) | 0.90 (0.70–1.15) |
|               |                     | LL        | 32 (12.4) | 22 (8.5) | 1.49 (0.82–2.71) | 26 (7.5) | 18 (6.1) | 1.17 (0.62–2.21) | 1.33 (0.86–2.05) | 1.33 (0.86–2.05) | 1.33 (0.86–2.05) |
|               |                     | Total     | 258       | 259       | 0.33        | 348       | 295       | 0.52        | 0.21        | 0.21        | 0.21        |
|               |                     | LL vs. SS + SL | 1.53 (0.86–2.70) | 0.15 | 1.24 (0.67–2.31) | 0.49 | 1.39 (0.91–2.12) | 0.13 |
|               |                     | SL + LL vs. SS | 1.04 (0.74–1.47) | 0.83 | 0.90 (0.66–1.23) | 0.51 | 0.96 (0.76–1.21) | 0.73 |

1S: Short allele; L: Long allele.

2P values < 0.083 were bolded.

doi:10.1371/journal.pone.0040494.t003
9–26; L: 18–34; Ave. 22.74±2.13) in AA controls, whereas it was 9 to 33 (S: 9–29; L: 19–33; Ave. 22.49±2.10) in NG cases and 9 to 33 (S: 9–26; L: 19–33; Ave. 22.49±2.05) in NG controls (Table 2, Figure 1).

When the repeat lengths of both ESR2_CA alleles were analyzed as continuous variables, AA cases appeared to have shorter L than AA controls (Mann-Whitney \( P = 0.036 \); logistic regression \( P = 0.04 \), OR = 0.91, 95% CI 0.83–1.00), whereas NG patients had longer S than NG controls (Mann-Whitney \( P = 0.0018 \); logistic regression \( P = 0.04 \), OR = 1.06, 95% CI 1.00–1.11) (Table 2). Thus, it turned out that L was the protective allele in AA and S was the risk allele in NG. In addition, it revealed that longer average repeat length of the ESR2_CA alleles was significantly more associated with breast cancer in NG (Mann-Whitney \( P = 0.0047 \); logistic regression \( P = 0.03 \), OR = 1.09, 95% CI 1.01–1.17) (Table 2). According to the categorical repeat length cut-off of 23, comparisons of the ESR2_CA genotypes between case and control groups showed no significance in either AA or AA + NG, but there was significance in NG (\( P = 0.0004 \)) (Table 3). NG individuals with SS and SL genotypes (enrichment of the risk allele, S) had significantly increased risk of developing breast cancer compared to the ones with LL genotype (\( P < 0.001 \), OR = 1.86, 95% CI 1.36–2.54) (Table 3). Similarly, the trend was also observed in AA + NG (\( P = 0.006 \), OR = 1.38, 95% CI 1.10–1.74) (Table 3).

### Distribution of AR_CAG Alleles in Cases and Controls

The microsatellite AR_CAG located in exon 1 of the AR gene has repeat length ranging from 10 to 32 (S: 10–26; L: 15–32; Ave. 20.04±2.38) in AA cases and 7 to 31 (S: 7–25; L: 14–31; Ave. 19.81±2.42) in AA controls, whereas it is 9 to 31 (S: 9–25; L: 15–31; Ave. 19.52±2.11) in NG cases and 11 to 29 (S: 11–25; L: 14–29; Ave. 19.56±2.22) in NG controls (Table 2, Figure 1).

No statistical significance was found between AA patients and controls in the analysis of continuous variables for the distribution of AR_CAG repeat polymorphism. AA cases carried longer S of AR_CAG than AA controls (Mann-Whitney \( P = 0.038 \); logistic regression \( P = 0.03 \), OR = 1.08, 95% CI 1.01–1.15). No statistically significant signal was obtained in either NG or AA + NG. In addition, we applied the dichotomous cut-offs of 20 and 22 for AR_CAG and then conducted genotypic logistic regression analysis. The results of this study provided no evidence that the AR_CAG genotypes can significantly influence the risk for breast cancer, in any populations (Table 3). Furthermore, the combined data set from us and Wang et al. [9] showed that there was no association of AR_CAG genotype and breast cancer risk in AA (SL + LL vs. SS, \( P = 0.61 \), OR = 1.07, 95% CI 0.82–1.38) (Table 4).

### Table 4. Association between AR_CAG (categorical cut-off = 22) and breast cancer in African American women.

| Genotype | AA (the present study) | AA (Wang, 2005 [9]) | AA (combined) |
|----------|------------------------|---------------------|---------------|
|          | Case, n (%) | Control, n (%) | OR (95% CI) | Case, n (%) | Control, n (%) | OR (95% CI) | Case, n (%) | Control, n (%) | OR (95% CI) |
| SS       | 124 (48.1) | 127 (49.0) | 1.0 (ref) | 145 (60.7) | 156 (62.7) | 1.0 (ref) | 269 (54.1) | 283 (55.7) | 1.0 (ref) |
| SL + LL  | 134 (51.9) | 132 (51.0) | 1.04 (0.74–1.47) | 94 (39.3) | 93 (37.3) | 1.09 (0.75–1.57) | 228 (45.9) | 225 (44.3) | 1.07 (0.82–1.38) |

1: S: Short allele; L: Long allele.

Discussion

Breast cancer is a hormone-dependent malignancy and cumulative exposure to sex hormones has been proposed to be linked to the development of breast cancer. Microsatellites ESR1_TA and ESR2_CA in the ESR1 and ESR2 genes, respectively, have also been reported to be associated with other diseases such as bone mineral density [10], osteoarthritis [11], and endometriosis [12]. Similarly, PolyGln tract of AR (encoded by AR_CAG) has been reported to be associated with susceptibility to a number of human diseases, such as prostate cancer, male infertility, cryptorchidism, hirsutism, Spinal and Bulbar Muscular Atrophy, and Kennedy’s disease, among others [8]. The ascertainment of ESR1_TA, ESR2_CA and AR_CAG in breast cancer have also been of scientific interest, especially on AR_CAG (Table 1). Nonetheless, the findings were not consistent with the AR_CAG genetic association studies that have been widely conducted in different racial/ethnic populations, except in those studying populations of African ancestry. In the present study, we targeted these three microsatellites and tested for germline susceptibility to female breast cancer, in two populations of African descent that were historically understood for breast cancer genetics: African Americans and Nigerians. ESR1_TA, ESR2_CA and AR_CAG were genotyped in 1,162 female individuals consisting of 258 AA breast cancer cases, 259 AA controls, 349 NG breast cancer patients, and 296 NG controls. We then compared the repeat lengths of these three microsatellites between case and control groups using statistical methods considering continuous or categorical variables. With 607 case patients and 555 controls, the current study provides 80% power at an alpha level of 0.05 to detect an OR of 1.39 if we assume that the probability of AR_CAG long alleles greater than 22 is 0.5, under a dominant genetic model according to previous study. For ESR1_TA and ESR2_CA, the study provides 80% power at an alpha level of 0.05 to detect an OR of 1.44 under a recessive genetic model or 1.49 under a dominant genetic model if we categorize these two microsatellites biomarkers according to the median. The power for detecting case-control difference is higher if we analyze these three microsatellites biomarkers as continuous variables.

Analyzing each individual allele of a microsatellite is a way to examine its genetic/biological function. However, it is not easy to test whether an effect from a combination of alleles exists, and which alleles are actually involved. The combination could rely on repeat length (joint effect from particular alleles of repeat-length-dependent functional property), or allele frequency (quantitative-like effect from any functional alleles reaches a threshold). It therefore creates too many assumptions and comparisons, especially when the function (if any) of exact allele(s) of a microsatellite remains unclear. Previous studies applied either the mean repeat length as a cut-off, or a cut-off previously reported, sometimes even ignoring the allele distribution differences among
different ethnic populations. We chose to set the mean repeat length as a cut-off, because it divides the distribution of microsatellite repeat lengths in approximately in half, maintains adequate numbers in each allele category, and therefore provides the greatest power to detect statistically significant differences between cases and controls.

Overall, the allele distributions of each individual microsatellite between AA and NG are similar (Figure 1). The allele distribution of AR_CAG in our AA is comparable to other AA cohorts [9]. Additionally, the spectrum of AR_CAG in the present study is consistent with previous observations that Africans have the shortest AR_CAG repeats, Asians bear the longest ones, while Caucasians and Mexican Americans are in the middle [13].

With the cut-off of ESR1_TA repeat length defined as 18, we found a \( P \) value of 0.039 in logistic regression in AA + NG, but not in AA or NG; however, this \( P \) value did not reach the significant threshold of 0.0003. Additionally, no statistical significance was observed in continuous variable analysis. It seems that the risk impact of ESR1_TA in breast cancer is weak or is very likely to be absent in AA and NG. A large case-control study of ESR1 haplotype and postmenopausal breast cancer risk in Sweden has been carried out, but the ESR1_TA genotypes distribution deviated from HWE [14]. Studies in French and Greek populations suggested that ESR1_TA does not contribute to the development of breast cancer in women [13,16].

In recent years, many genome-wide association studies (GWAS) have been conducted to search for breast cancer susceptibility loci. One of the GWAS hits, 6q25.1 (CCDC170-ESR1 region), was identified in a Chinese population [17]. The most significant single nucleotide polymorphism (SNP), rs2046210, is located 3’ downstream (6kb away) of CCDC170 and 5’ upstream (63 kb away) of the nearest ESR1 isoform 4, a region covered by a single linkage disequilibrium (LD) block. This SNP has been replicated in Chinese and Japanese populations [10] but not in African Americans [18-21]. Furthermore, fine-mapping studies suggested that rs9397435 (2.9 kb away from rs2046210) could confer risk to all three populations in women of Asian, European, and African origin [22]. These two SNPs are 119 kb away from ESR1_TA which is located in another LD block. Thus, the role of germline genetic variants of ESR1 in breast cancer etiology herein remains to be further clarified and explored. To date, neither ESR2 nor AR genes has been identified by breast cancer GWAS.

For ESR2_CA, our analysis of continuous variables showed that AA cases had shorter L than AA controls (Mann-Whitney \( P = 0.036; \) logistic regression \( P = 0.04, OR = 0.91, 95\% CI 0.93–1.00)\). Thus, L turned out to be the protective allele in AA. However, the association results were negative when considering multiple-testing correction. So, the inherited predisposition of AR_CAG and breast cancer risk in AA women. We were unable to perform multiple-testing correction. The inherited predisposition of AR_CAG has been reported to breast cancer risk in AA women [24], while longer repeats has been linked to less breast cancer risk in Greeks [16]. Our data were in line with the above observations in Romanians and Greeks.

The reversed association directions of ESR2_CA observed in our AA and NG cohorts, could be explained as a flip-flop phenomenon which has been frequently observed across different or even the same ethnic groups [25]. If a genetic variant is a functional causal variant (e.g., a confirmed missense mutation or splicing variant), its risk allele is supposed to be the same in different association tests, theoretically; if a flip-flop association occurs for a variant with unknown function (e.g., ESR2_CA or an intergenic SNP), it could indicate a false-positive or a true association – different risk alleles from different study populations tag/capture the same risk allele of another genuine causal variant in LD. In addition to different LD architectures, flip-flop associations could also be attributable to sample heterogeneity, sampling variations, nulllucious interactions, and gene-environment interactions, across different racial/ethnic populations. Although African Americans and Nigerians share ancestral origin, they have differences in lifestyle, environmental exposure, mutation selection balance, local recombination rate, LD pattern, among others. To the best of our knowledge, this is the first reported association of ESR2_CA and breast cancer risk in women of African ancestry; its flip-flop associations underscore the need for further and deeper validation in the same or similar populations.

Among the three microsatellites examined, AR_CAG is the most commonly tested one in the literature (Table 1). In the analysis of continuous variables, it showed that AA cases carried longer S of AR_CAG than AA controls (Mann-Whitney \( P = 0.036; \) logistic regression \( P = 0.03, OR = 1.09, 95\% CI 1.01–1.15)\), but no statistical significance was obtained after adjusting for multiple-testing. Furthermore, we did not gain any significant indications from logistic regression analysis when a dichotomized cut-off of 20 was applied. Wang et al. have genotyped AR_CAG in 239 AA breast cancer women and 249 controls and found no significant association between AR_CAG and overall breast cancer risk using a cut-off of 22 AR_CAG repeats [9]. Nonetheless, longer AR_CAG repeats were found to be associated with increased risk in AA women with a first-degree family history of breast cancer [9]. In order to compare our results to theirs, we also classified the AR_CAG repeat lengths using the same cut-off of 22. Our own data together with the results from the combined data set revealed no positive association between AR_CAG and breast cancer risk in AA women. We were unable to perform statistical comparisons in women with a first-degree family history of breast cancer, due to the very limited number of such individuals in the present study. Based on the results above, we can only cautiously draw a conservative conclusion that AR_CAG seems to influence the overall breast cancer risk weakly at most in AA, though it might affect the disease susceptibility to women having family history of breast cancer.

It is noteworthy that there have been divergent findings about the AR_CAG and breast cancer risk (Table 1). One possible explanation is that the previous studies applied different study designs (case-control study vs. case-only study), populations (Caucasians, Asians, etc.), subjects’ gender (female vs. male), sample size, DNA (germline vs. somatic), or dichotomous repeat length cut-offs. In addition, X-inactivation has been suspected to bias risk estimates, since \( AR \) is located on the X chromosome. However, it has been reported that the short and long AR_CAG alleles were subjected to skewed inactivation with similar frequency [26], and it has been suggested that X-inactivation might not be responsible to the estimation bias due to its early
occurrence in the embryo and later in the different lobes within the same breast [27].

Since it has become clear in recent years that breast cancer genetic susceptibility is subtype specific, we conducted similar subset analysis stratified by ER status but found no significance (Table S1 and Table S2). It is worth noting that we were unable to obtain sufficient statistical power for the subtype analysis due to the limited sample size. Our work is a retrospective study primarily designed for overall breast cancer risk. In addition, doing immunohistochemistry work in Nigeria is a challenge because scientific and medical support is still an emergent need there. Future investigations are warranted to determine the risk conferred by these three microsatellites in breast cancer patients classified by subtypes.

To our knowledge, there have been only three previous reports investigating the association between all the three microsatellites (ESR1_TA, ESR2_CA, and AR_CAG) and risk of breast cancer in women [15,16,24], and the present study is the first to evaluate the risk impact of these microsatellites in hormonal receptor genes and the germline susceptibility to breast cancer in an indigenous African population. The capability of these three microsatellites to estimate breast cancer risk requires further replications in larger and more diverse populations.

**References**

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10–29.
2. Jemal A, Bray F, Forman D, O’Connell M, Ferlay J, et al. (2012) Cancer burden in Africa and opportunities for prevention. Cancer doi: 10.1002/cncr.27410.
3. Bernstein L, Ross RK (1995) Endogenous hormones and breast cancer risk. Epidemiol Rev 15: 46–65.
4. Hankinson SE, Eliassen AH (2010) Circulating sex steroids and breast cancer risk in perimenopausal women. Horm Cancer 1: 2–10.
5. Russel J, Russo IH (2004) Genotoxicity of steroidal estrogens. Trends Endocrinol Metab 15: 211–214.
6. Maggolini M, Donze O, Jeannot E, Ando S, Picard D (1999) Adrenalin androstenedione stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor alpha. Cancer Res 59: 4864–4869.
7. Gemayel R, Vinces MD, Legendre M, Verstrepen KJ (2010) Variable tandem repeats accelerate evolution of coding and regulatory sequences. Annu Rev Genet 44: 445–477.
8. Palazollo I, Gloioza A, Rasumip P, Sau D, Crippa V, et al. (2008) The role of the polyclutinatinate in androgen receptor, J Steroid Biochem Mol Biol 108: 245–253.
9. Wang W, John EM, Ingles SA (2005) Androgen receptor and prostate-specific antigen gene polymorphisms and breast cancer in African-American women. Cancer Epidemiol Biomarkers Prev 14: 2890–2894.
10. Beckerina I, Lennard I, Masi L, Mamani R, Massar F, et al. (2000) Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor alpha gene and their relationship to bone mass variation in postmenopausal Italian women. Hum Mol Genet 9: 2043–2050.
11. Fytli P, Giannatou E, Papamikouvs A, Strilpis F, Karachalios T, et al. (2005) Association of repeat polymorphisms in the estrogen receptors alpha, beta, and androgen receptor genes with knee osteoarthritis. Clin Genet 68: 268–277.
12. Lamp M, Peters M, Reimma M, Halle-Pikkala K, Kaart T, et al. (2011) Polymorphisms in ESR1, ESR2 and HSD17B1 genes are associated with fertility status in endometriosis. Gynecol Endocrinol 27: 423–433.
13. Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R (1992) Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 12: 241–253.
14. Wedren S, Lovmar I, Humphreys K, Magnusson M, Melhus H, et al. (2004) Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study. Breast Cancer Res 6: R347–449.
15. Ishagin C, Lambert C, Normand M, Gemin C (2006) Microsatellite profile in hormonal receptor genes associated with breast cancer. Breast Cancer Res Treat 95: 153–159.
16. Tsezou A, Tzetzis M, Gennatas C, Giannatou E, Pampanos A, et al. (2008) Association of repeat polymorphisms in the estrogen receptors alpha, beta (ESR1, ESR2) and androgen receptor (AR) genes with the occurrence of breast cancer. Breast 17: 159–166.
17. Zheng W, Long J, Gao YT, Li C, Zheng Y, et al. (2009) Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 41: 324–328.
18. Cai Q, Wen W, Qi S, Li G, Egan KM, et al. (2011) Replication and functional genomic analyses of the breast cancer susceptibility locus at 6p25.1 generalize its importance in women of chinese, Japanese, and European ancestry. Cancer Res 71: 1344–1353.
19. Chen F, Chen GK, Millikan RF, John EM, Ambrosone CB, et al. (2011) Fine-mapping of breast cancer susceptibility loci characterizes genetic risk in African Americans. Hum Mol Genet 20: 4991–4993.
20. Hutter CM, Young AM, Ochs-Balcom HM, Carey CL, Wang T, et al. (2011) Replication of breast cancer GWAS susceptibility loci in the Women’s Health Initiative African American SHARc Study. Cancer Epidemiol Biomarkers Prev 20: 1950–1959.
21. Hsu D, Zheng Y, Ogundiran TO, Adebamowo C, Nathanson KL, et al. (2012) Evaluation of 19 susceptibility loci of breast cancer in women of African descent. Cancer Genet 201: 833–840.
22. Stacey SN, Sulem P, Zanon C, Gudjonsson SA, Thorleifsson G, et al. (2010) Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus. PLoS Genet 6: e1001029.
23. Forst A, Zhao C, Israelson E, Dohlimann-Wright K, Gustafsson JA, et al. (2003) Polymorphisms in the estrogen receptor beta gene and risk of breast cancer: no association. Breast Cancer Res Treat 79: 409–413.
24. Angel H, Raia M, Marian C, Ursanis O, Mitrus O (2006) Combined profile of the tandem repeats CAG, TA and CA of the androgen and estrogen receptor genes in breast cancer, J Cancer Res Clin Oncol 132: 727–733.
25. Lin PI, Vance JM, Pericak-Vance MA, Martin ER (2007) No gene is an island: the flip-dlop phenomenon. Am J Hum Genet 80: 531–538.
26. Calvo RM, Asuncion M, Sanchi J, San Millan JL, Escobar-Morreale HF (2000) The role of the CAG repeat polymorphism in the androgen receptor gene and of skewed X-chromosome inactivation, in the pathogenesis of hirsutism. J Clin Endocrinol Metab 85: 1735–1740.
27. Cox DG, Blanche H, Pearce CL, Calle EE, Colditz GA, et al. (2006) A comprehensive analysis of the androgen receptor gene polymorphisms and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Breast Cancer Res 8: R34.
28. Rebbeck TR, Kantoff PW, Krifivas K, Neuhusen S, Blackwood MA, et al. (1999) Modification of BRCA1-associated breast cancer risk by the polymorphic androgen receptor-CAG repeat. Ann J Hum Genet 64: 1371–1377.
29. Spurdle AB, Diet GS, Chen X, Mayne CJ, Southey MC, et al. (1999) Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years. J Nat Cancer Inst 91: 961–966.
30. Dunning AM, McBride S, Gregory J, Durocher F, Foster NA, et al. (1999) No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. Carcinogenesis: 20: 2131–2135.
31. Young JE, Kurtian KM, Mackenzie MA, Kunikle H, Cohen BB, et al. (2000) The CAG repeat within the androgen receptor gene in male breast cancer patients. J Med Genet 37: 139–140.
32. Given HF, Radbourne R, Oag H, Merritt S, Barclay E, et al. (2000) The association of repeat polymorphisms in the estrogen receptors alpha, beta, and androgen receptor genes with age of presentation in breast cancer. Eur J Cancer 36: 533–534.
33. Yu H, Bharaj B, Vassilikos EJ, Giai M, Diamandis EP (2000) Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. Breast Cancer Res Treat 59: 153–161.

**Supporting Information**

**Table S1** Continuous variable analysis of ESR1_TA, ESR2_CA, and AR_CAG alleles and breast cancer risk stratified by ER status in African American and Nigerian women.

**Table S2** Categorical variable analysis of ESR1_TA, ESR2_CA, and AR_CAG alleles and breast cancer risk stratified by ER status in African American and Nigerian combined samples.

**Acknowledgments**

We express our gratitude to all the women who have participated in this study. We thank Walmy E. Sreen and Rebecca Inledon for critical reading of the manuscript.

**Author Contributions**

Conceived and designed the experiments: YZ JZ OIO. Performed the experiments: YZ JZ TFY. Analyzed the data: YZ DH. Contributed reagents/materials/analysis tools: JZ QN. Wrote the paper: YZ DH JZ TFY OIO.
34. Menin C, Banna GL, De Salvo G, Lazzarotto V, De Nicola A, et al. (2001) Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer. Cancer Lett 168: 31–36.
35. Kadoury L, Easton DF, Edwards S, Hubbert A, Kote-Jarai Z, et al. (2001) CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer 85: 36–40.
36. Giguere Y, Dewailly E, Brison J, Ayotte P, Laflamme N, et al. (2001) Short polyglutamine tracts in the androgen receptor are protective against breast cancer in the general population. Cancer Res 61: 5869–5874.
37. Elhaji YA, Gottlieb B, Lumbroso R, Beitel LK, Foulkes WD, et al. (2001) The polyphoric CAG repeat of the androgen receptor gene: a potential role in breast cancer in women over 40. Breast Cancer Res Treat 70: 109–116.
38. Kristiansen M, Langerod A, Knudsen GP, Weber BL, Borresen-Dale AL, et al. (2001) Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat length polymorphism in the androgen receptor gene and breast cancer susceptibility in Finnish male breast cancer. Breast Cancer Res Treat 77: 167–170.
39. Dagan E, Friedman E, Paperna T, Carmi N, Gershoni-Baruch R. (2002) Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype. Eur J Hum Genet 10: 724–728.
40. Suter NM, Malone KE, Daling JR, Doody DR, Ostrander EA (2003) Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women. Cancer Epidemiol Biomarkers Prev 12: 1045–1049.
41. Suter NM, Malone KE, Daling JR, Doody DR, Ostrander EA (2003) Androgen receptor gene alterations in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype. Eur J Hum Genet 10: 724–728.
42. Syrjakoski K, Hyytinen ER, Kuukasjarvi T, Auvinen A, Kallioniemi OP, et al. (2002) High frequency of skewed X inactivation in young breast cancer patients. J Med Genet 39: 30–33.
43. Liede A, Zhang W, De Leon Matsuda ML, Tan A, Narod SA (2003) Androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 88: 239–246.
44. MacLean HE, Brown RW, Beilin J, Warne GL, Zajac JD (2004) Increased risk of breast cancer in women bearing a combination of large CAG and GGN repeats in the exon 1 of the androgen receptor gene. Eur J Cancer 43: 2373–2380.
45. Wedren S, Magnusson C, Humphreys K, Melhus H, Kindmark A, et al. (2007) Associations between androgen and vitamin D receptor microsatellites and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 16: 1775–1783.
46. Slattery ML, Sweeney C, Herrick J, Wolff R, Baumgartner K, et al. (2007) ESR1, AR, body size, and breast cancer risk in Hispanic and non-Hispanic white women living in the Southwestern United States. Breast Cancer Res Treat 105: 327–335.
47. Gonzalez A, Javier Dorta F, Rodriguez G, Brito B, Rodriguez MA, et al. (2007) Increased risk of breast cancer in women bearing a combination of large CAG and GGN repeats in the exon 1 of the androgen receptor gene. Eur J Cancer 43: 2373–2380.